Algae-Derived Peptides: Seaweed as Food
Marine Bioactive Peptides
IC50 0.28 \u00B5M
A novel ACE-inhibitory peptide from Chlorella pyrenoidosa achieved nanomolar potency, among the strongest marine-derived enzyme inhibitors reported.
Suo et al., Int J Biol Macromol, 2024
Suo et al., Int J Biol Macromol, 2024
View as imageSeaweed has been a dietary staple in East Asian cuisines for centuries. Japan, Korea, and China consume tens of thousands of tons annually in forms ranging from nori sheets to kombu broth. What traditional food cultures understood intuitively, peptide researchers are now quantifying: the proteins in marine algae, when broken down by digestive enzymes or industrial hydrolysis, release bioactive peptide fragments with measurable effects on blood pressure regulation, oxidative stress, and glucose metabolism. This article examines the research landscape for algae-derived bioactive peptides, covering the major algae species studied, the bioactivities identified, the methods used to produce and characterize these peptides, and the gaps between laboratory findings and clinical evidence. For the broader context of marine peptide research, see Marine Bioactive Peptides: The Ocean as a Source of Health Compounds.
Key Takeaways
- Seaweed protein content ranges from 5-47% of dry weight depending on species, with red algae (Porphyra, Palmaria) generally containing the highest protein levels (Echave et al., 2022)
- ACE-inhibitory peptides isolated from Ulva prolifera achieved IC50 values as low as 11.64 micromolar, with molecular docking confirming binding to the ACE active site (Li et al., 2023)
- A Chlorella pyrenoidosa-derived peptide demonstrated nanomolar ACE inhibition (IC50 = 0.28 micromolar) with unusual binding involving both the S1 and S2 subsites of ACE (Suo et al., 2024)
- Spirulina-derived peptides encapsulated in nanoliposomes accelerated full-thickness wound closure in animal models (Ebrahimi et al., 2023)
- Dual-target peptides from Chlorella simultaneously inhibited ACE and alpha-amylase, addressing cardiovascular and diabetic pathways with a single molecule (Yu et al., 2025)
- Most evidence comes from in vitro assays and animal models; no large-scale human clinical trials of purified algae peptides have been published
Why Algae as a Peptide Source
Over 10,000 species of algae have been identified, divided broadly into macroalgae (seaweeds visible to the naked eye) and microalgae (single-celled organisms like Chlorella and Spirulina). Both categories contain proteins that, upon enzymatic digestion, release short peptide fragments (typically 2-20 amino acids) with biological activity.[1]
Three features make algae attractive as peptide sources. First, protein content in some species is substantial: red algae like Porphyra (nori) contain 35-47% protein by dry weight, comparable to soybeans. Green algae (Ulva, Chlorella) range from 10-26%, and brown algae (Sargassum, Undaria) typically contain 5-15%.[2] Second, algae grow rapidly without requiring arable land, freshwater, or fertilizer, making them a sustainable protein source. Third, the amino acid profiles of algae proteins are often rich in glutamic acid, aspartic acid, and hydrophobic residues that are characteristic of bioactive peptide sequences.
The protein in intact seaweed cells is not automatically bioactive. Bioactive peptides are released when algae proteins are cleaved at specific sites by proteolytic enzymes. This happens naturally during gastrointestinal digestion, or it can be engineered through in vitro hydrolysis using enzymes like pepsin, trypsin, alcalase, or papain.[1]
For other food-derived peptide sources, see Antioxidant Peptides from Food: Fighting Free Radicals with Diet and How Fermentation Creates Bioactive Peptides.
ACE-Inhibitory Peptides: The Blood Pressure Connection
The most extensively studied bioactivity of algae-derived peptides is inhibition of angiotensin-converting enzyme (ACE), the same target as pharmaceutical ACE inhibitors like lisinopril and enalapril. ACE converts angiotensin I to angiotensin II, a potent vasoconstrictor. Blocking ACE lowers blood pressure.
Ulva prolifera (Sea Lettuce)
Li and colleagues (2023) isolated and identified ACE-inhibitory peptides from Ulva prolifera using alcalase hydrolysis followed by ultrafiltration and chromatographic separation. They identified three peptides with IC50 values ranging from 11.64 to 37.28 micromolar. Molecular docking analysis confirmed that these peptides interacted directly with the ACE active site through hydrogen bonding and hydrophobic interactions with key residues (Glu162, His353, Ala354, and Zn2+).[3]
In a follow-up study, Li et al. (2024) investigated the vasodilation mechanism of an Ulva prolifera-derived ACE inhibitory peptide and found that it relaxed vascular smooth muscle through nitric oxide-dependent pathways, providing a mechanism beyond simple enzyme inhibition for how these peptides might lower blood pressure in vivo.[4]
Chlorella pyrenoidosa
Suo and colleagues (2024) discovered a novel nanomolar ACE inhibitor from Chlorella pyrenoidosa with an IC50 of 0.28 micromolar. This is among the most potent ACE-inhibitory peptides ever reported from any food source. The peptide exhibited unusual binding mechanics: rather than occupying only the S1 subsite (as most food-derived ACE inhibitors do), it simultaneously engaged the S1 and S2 subsites of ACE, creating a more stable enzyme-inhibitor complex.[5]
Nanoliposomal Delivery
Sensu and colleagues (2025) addressed one of the main challenges of peptide therapeutics: delivery. They encapsulated ACE-inhibitory peptides from Ulva rigida in nanoliposomes, which improved peptide stability during simulated gastrointestinal digestion and enhanced cellular uptake. The nanoliposomal formulation maintained ACE-inhibitory activity after passage through acidic stomach conditions that would normally degrade free peptides.[6]
For how pharmaceutical ACE inhibitors work at the molecular level, see ACE Inhibitors: How Blocking a Peptide Enzyme Lowers Blood Pressure. For food-derived ACE-inhibitory peptides from non-algae sources, see ACE-Inhibitory Peptides in Food: Natural Blood Pressure Management.
Antioxidant Properties
Algae-derived peptides scavenge free radicals and chelate pro-oxidant metal ions. The antioxidant activity of these peptides is typically attributed to their amino acid composition: histidine, tyrosine, methionine, cysteine, and tryptophan residues donate electrons to neutralize reactive oxygen species.[7]
Hydrolysates from red, green, and brown algae have demonstrated antioxidant activity in cell-free assays (DPPH, ABTS, FRAP), cell culture models (protecting HepG2 cells from hydrogen peroxide-induced damage), and in animal models. The challenge is that in vitro antioxidant activity does not reliably predict in vivo efficacy, because peptides must survive digestion, cross the intestinal epithelium, and reach target tissues at sufficient concentrations.
Shannon and colleagues (2025) evaluated three seaweed species commonly consumed in Europe (Alaria esculenta, Ulva lactuca, Palmaria palmata) for their potential as functional food ingredients targeting metabolic syndrome. They found that protein hydrolysates from all three species showed antioxidant and anti-inflammatory activities in vitro, but the bioactive profiles differed substantially between species, underscoring that "seaweed" is not a monolithic category.[8]
Antidiabetic Peptides
Several algae-derived peptides inhibit alpha-amylase and alpha-glucosidase, enzymes that break down complex carbohydrates into glucose. Blocking these enzymes slows glucose absorption after meals, a mechanism shared with the pharmaceutical drug acarbose.[7]
Dual-Target Inhibitors from Chlorella
Yu and colleagues (2025) developed an enzyme-immobilized affinity membrane to efficiently screen dual-target peptides from Chlorella. They identified peptides that simultaneously inhibited ACE and alpha-amylase, addressing both cardiovascular and glycemic dysregulation with a single molecular entity. The screening method itself was a methodological advance: by immobilizing both target enzymes on the same membrane, they could identify multifunctional peptides in a single step rather than requiring sequential screening against each target.[9]
Microalgae as Delivery Platforms
Boscart and colleagues (2026) reviewed the use of plant and microalgae as biotechnological platforms for producing and delivering antidiabetic peptides. Microalgae like Chlorella and Chlamydomonas can be engineered to express recombinant therapeutic peptides (including insulin analogs) within their cells, which then serve as edible delivery vehicles. This approach could reduce the cost of peptide therapeutics while providing natural encapsulation that protects peptides from gastric degradation.[10]
Spirulina: The Most-Studied Microalga
Spirulina (Arthrospira platensis) deserves special mention because it is the most commercially available and most extensively researched microalga for peptide bioactivities.
Wound Healing
Ebrahimi and colleagues (2023) demonstrated that peptides derived from Spirulina platensis protein, when encapsulated in nanoliposomes, accelerated full-thickness wound closure in a rat model. The nanoliposomal formulation was critical: free peptides showed modest wound healing activity, but nanoliposomal encapsulation improved both peptide stability and skin penetration, resulting in faster epithelialization and collagen deposition.[11]
Digestion-Released Peptides
Fortuin and colleagues (2025) used proteomic and peptidomic profiling to characterize the peptides released when spirulina-fortified probiotic powder was subjected to simulated in vitro digestion. They found that gastrointestinal digestion released a diverse array of peptides from spirulina proteins, including sequences previously identified as having antioxidant, anti-inflammatory, and ACE-inhibitory properties. This study is useful because it shows what happens to spirulina protein under realistic digestive conditions, not just under laboratory hydrolysis with a single enzyme.[12]
The Comprehensive Review Landscape
Wang and colleagues (2025) published a comprehensive review of seaweed-derived proteins and peptides, covering preparation methods, virtual screening techniques, health-promoting effects, and industry applications. They noted that while hundreds of bioactive peptide sequences have been identified from seaweed sources, most have only been characterized in vitro. The review identified antihypertensive, antioxidant, antidiabetic, anti-inflammatory, and antimicrobial activities as the five most commonly reported bioactivities for seaweed peptides.[1]
Admassu and colleagues (2018) specifically reviewed the antihypertensive, antioxidant, and antidiabetic properties of seaweed-derived bioactive peptides, noting that enzymatic hydrolysis remained the most effective production method and that peptide activity was strongly influenced by amino acid composition, sequence, chain length, and hydrophobicity.[7]
Echave and colleagues (2022) cataloged the major protein fractions in seaweed (phycobiliproteins in red algae, glycoproteins, lectins, peptides, and mycosporine-like amino acids) and reviewed the evidence for their biological activities. They emphasized that the health benefits attributed to seaweed consumption in Asian populations may be partly mediated by bioactive peptides released during digestion, though isolating this effect from other seaweed components (polysaccharides, polyphenols, minerals) is difficult.[2]
From Bench to Plate: The Translational Gap
The gap between laboratory findings and practical applications for algae peptides is substantial. Several factors account for this.
Bioavailability is unresolved. Most algae peptides are tested in vitro, where they contact target enzymes directly. In vivo, peptides must survive gastric acid, resist pancreatic protease degradation, cross the intestinal mucosa, and reach systemic circulation. Nanoliposomal encapsulation improves these properties,[6] but adds cost and complexity.
Human clinical data is scarce. Some commercial seaweed peptide products exist in Japan (Nori S Peptide, Wakame jelly) with FOSHU (Foods for Specified Health Uses) approval for blood pressure management. However, these approvals are based on limited clinical data by Western regulatory standards. No large randomized controlled trials of purified algae peptides for hypertension, diabetes, or oxidative stress have been published in Western medical journals.
Standardization is lacking. The peptide profile of a seaweed hydrolysate depends on the algae species, growth conditions, harvest season, extraction method, enzyme used, hydrolysis time, and temperature. Two batches of "seaweed peptide" from the same species processed differently can have completely different peptide compositions and biological activities.
Single-peptide potency versus whole-hydrolysate effects. Some of the most impressive IC50 values (like Suo et al.'s 0.28 micromolar ACE inhibitor) come from purified single peptides. In a whole food context, the active peptide would be one component among thousands, present at unknown concentrations. The functional food angle and the pharmaceutical angle are fundamentally different approaches with different evidence requirements.
For how fish collagen peptides differ from algae-derived peptides in their health applications, see that sibling article.
The Bottom Line
Algae and seaweed are genuine sources of bioactive peptides with demonstrated ACE-inhibitory, antioxidant, and antidiabetic properties in laboratory settings. Peptides from Ulva, Chlorella, Spirulina, and Porphyra have been isolated, sequenced, and characterized with high biochemical rigor. However, the field remains predominantly preclinical. The translation from IC50 values in a test tube to measurable health benefits in humans consuming seaweed products has not been established through controlled clinical trials. Algae peptides represent a promising but unproven category of functional food bioactives.